From 41cd5b1da5cdb5fd817e9e3dd0b8a31fed3c55b4 Mon Sep 17 00:00:00 2001 From: FMS Date: Thu, 4 Apr 2024 16:50:17 +0200 Subject: [PATCH] Auto saved by Logseq --- journals/2024_04_04.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/journals/2024_04_04.md b/journals/2024_04_04.md index b9f34079..557cd322 100644 --- a/journals/2024_04_04.md +++ b/journals/2024_04_04.md @@ -70,7 +70,7 @@ - AK: We have hypothesis: people working in the vet world have shown that having a longer exposure to the drug improve the efficacy. We haven't completed the genomic analysis trying to identify if there is a difference. But the pharmacokinetic analysis shows in Phase II we couldn't identify. We only saw it in blood, not where the parasite is. - PL: The work being done by Sanger is it full genome analysis? - AK: sí. su approach también es ese para este proyecto. - - + - JOHN AMUASI: really a rich presentation of the clinical data. Quite a significant variation in the AE. - - - ## Cosas de gastos del [[Evento]]